Wr Pri LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$543,107	29
2024	Research	$1,783,732	109
2023	Research	$3,168,425	105
2022	Research	$84,621	11
2021	Research	$41,183	8
2019	Research	$463,332	4

Breakdown

Who paid Research payments · program years 2019–2025

Moderna TX, Inc. $4,012,760 167 payments
Bavarian Nordic A/S $1,402,338 55 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $544,306 11 payments
Pfizer Inc. $82,161 20 payments
Biohaven Pharmaceutical Holding Company Ltd. $29,808 9 payments
Sage Therapeutics, Inc. $13,028 4 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $3,480,391 142 payments
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 $1,378,338 51 payments
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age $532,369 25 payments
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficithyperactivity Disorder Trial 405-201-00014 $181,155 1 payment
An Open-Label, 52-Week, Multicenter Trial Evaluating the Long-Term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficithyperactivity Disorder $147,515 2 payments
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficithyperactivity Disorder Trial 405-201-00013 $134,662 1 payment
A Multi-Center, Randomized, Controlled Trial to Evaluate the Effectiveness of A Digital Therapeutic (CT-152) As Adjunctive Therapy in Adult Subjects Diagnosed With Major Depressive Disorder $68,817 3 payments
A Phase 4 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens $62,098 21 payments
A Phase 23 Randomized Doubleblind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $31,130 2 payments
Nct05329220 $24,000 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.